Product Images Methylphenidate Hydrochloride

This is a figure depicting the mean methylphenidate plasma concentrations in 36 adults after receiving a single dose of methylphenidate hydrochloride extended-release tablets of 18 mg once daily and immediate-release methylphenidate of 5 mg three times daily administered every 4 hours. There is no other available information in the given text.*

This is a figure that shows the mean Inattention/Overactivity Scores of Community School Teachers treated with methylphenidate hydrochloride extended-release tablets once daily at different dosages (18, 36, or 54 mg) and placebo in three different studies. The first two studies involved a 3-way crossover of 1 week per treatment arm, while the third study involved 4 weeks of parallel-group treatments. The figure includes error bars representing the mean plus standard error of the mean.*

This is a graph titled "Figure 3" which displays SKAMP ratings of laboratory school teachers. The mean (SEM) of the combined attention from two studies is shown. The graph includes a combined attention subscale and various attentive hours post initial dose. The x-axis ranges from 0 to 8 and includes the values 3, 5, and 7. The y-axis ranges from 0 to 25 and includes values in intervals of 5. No further information is available.*

This text provides information on the recommended starting doses and dose ranges of methylphenidate hydrochloride extended-release tablets for different age groups. The recommended starting dose for children aged 6-12 is 18 mg/day with a dose range of 18 mg - 54 mg/day. Adolescents aged 13-17 are also advised to start with 18 mg/day with a dose range of 18 mg - 72 mg/day not exceeding 2 mg/kg/day. Adults between the ages of 18-85 are recommended to take either 18 or 36 mg/day with a dose range of 18 mg - 72 mg/day.*

This is a table containing recommended dose conversions from Methylphenidate regimens to Methylphenidate Hydrochloride Extended-Release Tablets. The table lists the previous Methylphenidate daily dose and the recommended starting dose of Methylphenidate Hydrochloride Extended-Release Tablets.*

The table shows the exposure of Methylphenidate Hydrochloride Extended-Release Tablets in double-blind and open-label clinical studies for children, adolescents, and adults. It includes the patient population, sample size (N), and the dose range administered once daily for each population.*

This is a table showing the adverse reactions reported by more than 1% of children and adolescent subjects treated with Methylphenidate Hydrochloride Extended-Release Tablets in four placebo-controlled, double-blind clinical trials. The table lists the system/organ class, the adverse reaction, and the percentage of patients who experienced it while on the medication versus the placebo. The adverse reactions reported include gastrointestinal disorders, general disorders and administration site conditions, infections and infestations, nervous system disorders, psychiatric disorders, and respiratory, thoracic, and mediastinal disorders. The text provides useful information for healthcare professionals prescribing this medication.*

Table 6 shows adverse reactions reported by subjects who took 21% of Methylphenidate Hydrochloride extended-release tablets in two placebo-controlled, double-blind studies. The table includes different categories of adverse events with the percentage of subjects who experienced them. Some of the categories are gastrointestinal disorders, nervous system disorders, headache, and infections.*

Table 6 shows the pharmacokinetic parameters (Cmax, Tmax, and AUC) of Methylphenidate hydrochloride extended-release tablets in comparison to Methylphenidate immediate-release tablets in healthy adults after a single dose. The values are expressed as Mean ± SD with respect to the number of subjects in each group.*

This is a description of a medication called NILD - Methylphenidate Hydrochloride Extended-Release Tablets. The medication comes in 54mg tablets that should be kept out of reach of children and stored at a temperature of 20°C to 25°C. It needs to be dispensed in a tight, light-resistant container with a child-resistant closure. The National Drug Code (NDC) for this medication is 63629-1904-1, and it's only available with a prescription.*